Is IRWD a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

644 people get IRWD articles and Market Currents by email alert.

Get email alerts on IRWD »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

Consider Ironwood Pharmaceuticals Amidst Strong Insider Support
Kevin Quon • Tue, Nov 13, 2012
Ironwood Pharma: FDA Decision Expected Within Weeks For GI Drug
Mike Havrilla • Thu, Aug 16, 2012 • 1 Comment
5 Reasons To Buy Ironwood Pharmaceuticals
Markus Aarnio • Mon, May 28, 2012 • 9 Comments
Ironwood Pharma: First Biotech IPO of 2010
SA Editor Abbi Adest • Mon, Feb 1, 2010 • 1 Comment

To learn more about Seeking Alpha Pro, click here.

Synergy Is A Straightforward Opportunity: Trial Results At DDW Back Plecanatide
PropThink • Tue, May 21 • 16 Comments
The Compelling Science Behind Synergy
Veziris Ventures • Mon, Apr 29 • 5 Comments
Synergy On Sale: Why This Opportunity Shouldn't Be Missed
PropThink • Thu, Apr 25 • 11 Comments
Ram Selvaraju: Fall In Love With These Biotech Stocks
Life Sciences Report • Thu, Feb 14 • 1 Comment
VIX - Options Volatility And Market Sonar: Tuesday Recap
Erick McKitterick • Tue, Feb 12 • 2 Comments
Positive Top Line Data For Synergy: A Ripe Time For Acquisition
Logical Assessment • Wed, Jan 30 • 8 Comments
Cramer's Mad Money - Is This The End For Herbalife? (1/17/13)
SA Editor Miriam Metzinger • Fri, Jan 18 • 2 Comments
Stock Watch Tuesday, 15 January
VFC's Stock House • Tue, Jan 15 • 11 Comments
5 Biotech Stocks To Go Long Now
Scott Matusow • Fri, Nov 9, 2012 • 12 Comments
5 Healthcare Companies With Insider Buying During November 2012 - Part II
Markus Aarnio • Wed, Nov 7, 2012 • 2 Comments
A Capital-Efficient Prescription For New Drugs: Raghuram 'Ram' Selvaraju
Life Sciences Report • Thu, Nov 1, 2012 • 3 Comments
China Biotech In Review: U.S. Medical Device Makers Turn Attention To 2nd And 3rd Tier Cities
ChinaBio Today • Sun, Oct 28, 2012 • 1 Comment
Ironwood Implies Upside For Synergy; Lessons Learned From Dendreon
Logical Assessment • Thu, Oct 25, 2012 • 10 Comments
Synergy Pharmaceutical Could Almost Double In Value With Plecanatide
John Mylant • Thu, Oct 25, 2012 • 4 Comments
Synergy Pharma: Plecanatide Topline Data To Serve As Catalyst For Stock
Vineet Dutta • Wed, Oct 24, 2012
Weekly Stock Watch, Week Of September 24
VFC's Stock House • Tue, Sep 25, 2012 • 9 Comments
Synergy Pharmaceuticals: Positioning For Pipeline Payoff
VFC's Stock House • Wed, Sep 19, 2012 • 7 Comments
The 20 Most Popular Stocks On Seeking Alpha Over The Last Month
Contextuall • Thu, Sep 13, 2012 • 10 Comments
Weekly Stock Watch: Week Of 4 September
VFC's Stock House • Tue, Sep 4, 2012 • 6 Comments
Simple Math Showing Why Synergy Pharmaceuticals Is Undervalued
Shane Blackmon • Thu, Aug 30, 2012 • 16 Comments

Ironwood Pharmaceuticals' Management Hosts 2013 Annual Shareholder Meeting (Transcript)
Tue, Jun 4
Ironwood Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript
Tue, Apr 23
Ironwood Pharmaceuticals' CEO Hosts the Q4 2012 Investor Update Conference Call (Transcript)
Tue, Jan 15 • 2 Comments
Ironwood Pharmaceuticals' Management Presents at Credit Suisse 2012 Healthcare Conference (Transcript)
Thu, Nov 15, 2012
Ironwood Pharmaceuticals' CEO Hosts the 3Q 2012 Investor Update Conference Call - (Transcript)
Tue, Oct 16, 2012
Ironwood Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript
Tue, Jul 17, 2012

Ironwood Pharmaceuticals Announces Partial Exercise of Underwriters’ Option in Public Offering of Common Stock

Business Wire (Jun 4, 2013)
Ironwood Pharmaceuticals Prices Public Offering of Common Stock

Business Wire (May 21, 2013)
Ironwood Pharmaceuticals Announces Proposed Public Offering of Common Stock

Business Wire (May 20, 2013)
Ironwood and Forest to Present Linaclotide Data at Digestive Disease Week® 2013

Business Wire (May 14, 2013)
Ironwood Pharmaceuticals to Present at Bank of America Merrill Lynch 2013 Health Care Conference

Business Wire (May 7, 2013)
Ironwood Pharmaceuticals Provides First Quarter 2013 Investor Update

Business Wire (Apr 23, 2013)
Ironwood Pharmaceuticals to Host First Quarter 2013 Investor Update Call

Business Wire (Apr 2, 2013)
Ironwood Pharmaceuticals Appoints Edward Owens to Board of Directors

Business Wire (Mar 4, 2013)
Ironwood Pharmaceuticals to Present at Cowen and Company 33rd Annual Health Care Conference

Business Wire (Feb 25, 2013)
Ironwood Pharmaceuticals Promotes Dr. Mark Currie to Senior Vice President, Chief Scientific Officer, and President of R&D

Business Wire (Feb 11, 2013)
Cramer's Stock Calls: Ironwood Pharma, Santarus

at CNBC.com (Jan 17, 2013)
Ironwood Pharmaceuticals Provides Fourth Quarter 2012 Investor Update

Business Wire (Jan 15, 2013)
Lightning Round: Fortress, GNC & More

at CNBC.com (Jan 14, 2013)
Ironwood Pharmaceuticals to Host Fourth Quarter 2012 Investor Update Call

Business Wire (Jan 10, 2013)
Ironwood Completes $175 Million Debt Offering

Business Wire (Jan 4, 2013)
Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

Business Wire (Jan 2, 2013)
Ironwood and Forest Announce U.S. Availability of LINZESS™ (Linaclotide)

Business Wire (Dec 17, 2012)
Protagonist and Ironwood Expand Peptide Drug Discovery Collaboration

Business Wire (Dec 6, 2012)
Constella® (linaclotide) Approved in Europe for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in Adults

Business Wire (Nov 28, 2012)
Ironwood Pharmaceuticals to Present at the Credit Suisse 2012 Healthcare Conference

Business Wire (Nov 9, 2012)

IRWD vs. ETF Alternatives

Company Description

Currently, there's no company description for IRWD.

Sector: Healthcare

Industry: Medical Laboratories & Research

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, June 4, 4:22 PM Underwriters for Ironwood Pharmaceuticals' (IRWD) recent public offering partially exercise their option to purchase additional shares, buying a total of 704,948 units at $13, bringing the total number of shares issued in the deal to 11.2M. Shares are down fractionally AH. (PR) Comment! [Healthcare]
Thursday, May 30, 8:37 AM Wedbush's Gregory Wade reverses course and upgrades Ironwood Pharmaceuticals (IRWD) to Neutral from Underperform — he downgraded the shares a little over a month ago after asking some pointed questions regarding R&D expenditures on the CC. Wade now says higher W/W script growth should lead to greater net sales of Linzess (IRWD disappointed with Linzess sales in Q1) which ultimately means a lower balance sheet gap to profitability ($150M versus $200M). Wade also says the company shouldn't need any more equity financing. Shares +1% premarket. Comment! [Healthcare]
Wednesday, May 22, 1:34 PM Ironwood Pharmaceuticals (IRWD -5%) slips after pricing its previously announced 10.5M share offering at $13 per share. All shares are being offered by the company, and proceeds are expected to be around $136.5M. The company intends for net proceeds to support the commercial launch of Linzess as well as support general research and development within the Company's pipeline. Comment! [Healthcare, On the Move]
Monday, May 20, 4:14 PM Ironwood Pharmaceuticals (IRWD) announces a 10.5M share public offering, with a 30-day option to purchase up to an additional 1,575,000 shares. All of the shares are being offered by the company, which plans to use the proceeds to support the commercial launch of Linzess in the U.S. and to fund linaclotide development opportunities to strengthen the clinical profile of the drug and expand the product label for additional populations and indications. Shares +0.7% AH. 1 Comment [Healthcare]
Wednesday, April 24, 12:13 PM Ironwood Pharmaceuticals (IRWD -3.5%) (which yesterday reported a Q1 miss and underwhelmed with sales of its IBS drug Linzess) falls again as Morgan Stanley downgrades to Equal-Weight despite projecting "a competitive cost/benefit" Linzess profile. Meanwhile, Wedbush's Gregory Wade downgrades the shares to Underperform. "Can you help us understand where the money is going?" Wade asked on the call, referring to ongoing Linzess-related R&D expenditures that appear to be more than 5X his estimates. "It's really just the cost of operating the business," CFO Michael Higgins responded. (transcript) Comment! [Healthcare, On the Move]
Tuesday, April 23, 11:06 AM Ironwood Pharmaceuticals (IRWD -4.5%) slides on a big Q1 miss this morning. Revenue dropped 73% Y/Y on weak sales of its IBS drug Linzess, while losses widened significantly as its bottom line was hit hard by a 92% rise in total costs - due largely to the rollout of Linzess - and an 11% jump in R&D expenses. Comment! [Healthcare, On the Move, Earnings]
Tuesday, April 23, 9:28 AM Ironwood Pharma (IRWD): Q1 EPS of -$0.87 misses by $0.18. Revenue of $3.26M misses by $5.68M. Shares -9.7% premarket. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
Tuesday, April 23, 9:10 AM Premarket gainers: MEMS +50%. SCON +46%. NFLX +24%. VECO +14%. COH +12%. ILMN +10%. ARMH +9%. CZR +8%. STM +6%. AMRN +6%.
Losers: IRWD -10%. RSH -7%. IOC -6%. Comment! [On the Move]
Tuesday, April 23, 8:30 AM Ironwood Pharmaceuticals (IRWD) sinks 13.3% premarket after saying sales of Linzess — the IBS drug the company markets with Forest Labs (FRX) — were $4.5M for Q1 versus expectations of $11-13M. Credit Suisse and Wedbush previously said early evidence suggested demand for the drug was strong. Irina Rivkind at Cantor says Synergy's (SGYP) investigational candidate plecanatide has the potential to achieve revenue parity with Linzess. Comment! [On the Move, Healthcare]
Tuesday, April 23, 12:05 AM Notable earnings before Tuesday’s open: ACI, AKS, AOS, APD, ARMH, CIT, CNC, COH, DAL, DD, DFS, EAT, ECA, FMER, FRX, GCI, GNTX, IDXX, IIVI, IR, IRWD, ITW, JCI, JNS, LCC, LECO, LMT, LXK, MOLX, PCAR, PCH, PII, PMT, PNR, R, RAI, RF, RSH, SNV, ST, TRV, UTX, WAT, XRX 1 Comment [Earnings]
Monday, April 22, 5:30 PM Notable earnings before Tuesday’s open: ACI, AKS, AOS, APD, ARMH, CIT, CNC, COH, DAL, DD, DFS, EAT, ECA, FMER, FRX, GCI, GNTX, IDXX, IIVI, IR, IRWD, ITW, JCI, JNS, LCC, LECO, LMT, LXK, MOLX, PCAR, PCH, PII, PMT, PNR, R, RAI, RF, RSH, SNV, ST, TRV, UTX, WAT, XRX Comment! [Earnings]
Tuesday, April 9, 11:44 AM Synergy Pharmaceuticals (SGYP +10.3%) soars on heavy volume after Cantor Fitzgerald raises its price target on the shares to $15 from $12. Irina Rivkind says the company's lead investigational drug plecanatide can "achieve revenue parity" with Ironwood (IRWD -0.5%) and Forest Laboratories' (FRX -0.2%) Linzess, an FDA approved treatment for constipation. Comment! [Healthcare, On the Move]
Friday, March 15, 2:05 PM Ironwood Pharmaceuticals (IRWD +4.7%) trades up after Credit Suisse raises the shares to Outperform and raised its price target to $24 from $15. The firm says IRWD is poised to see strong demand for its IBS drug Linzess, based on a survey of 100 physicians. Comment! [Healthcare, On the Move]
Wednesday, February 13, 1:41 PM Ironwood Pharmaceuticals (IRWD +0.9%) gains on an upgrade to Neutral today from Wedbush. The firm notes that early script data for Q1 suggests strong week-over-week Linzess growth, which, if sustained, would see Q1 and FY13 end-user demand well ahead of initial estimates. Comment! [Healthcare, On the Move]
Wednesday, January 16, 2:51 PM Shares of Ironwood Pharmaceuticals (IRWD -7.5%) slide after posting a Q4 earnings beat yesterday, but posting a 16% Y/Y decline in total revenue. UBS cut the shares to Sell this morning after the report. Comment! [Healthcare, On the Move]
Wednesday, January 16, 12:45 PM Midday top 10 gainers: CLRO +49%. NVTL +17%. HPTX +16%. FSGI +16%. CBK +14%. PLBC +13%. BOSC +13%. FSI +12%. CYTR +10%. ADES +10%.
Midday top 10 Losers: GALT -9%. LODE -8%. AMRS -8%. PGNX -8%. IRWD -7%. CROX -7%. GDOT -7%. AXX -7%. YOD -7%. AIM -7%. Comment! [On the Move]

bigdaddyvt84
Credit Suisse analyst Catherine Arnold upgraded her rating on $IRWD to "Outperform" and raised the price target to $24.
Mar 15, 3:33 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

VFC's Stock House
Stock Watch Wednesday: $BA, $FB, $GOOG, $WFC, $GS, $JPM, $IRWD, $FRX, $ONVO.PK, $DDD, $SYSS, $AAPL - http://bit.ly/cAHZ42
Jan 16, 7:09 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

VFC's Stock House
Weekly Stock Watch- $AAPL, $AMRN, $DNDN, $IMSC.PK, $SGYP, $IRWD, $TTNP.OB, $LPTN, $PFE, $MCD, $YUM, $CELH.OB - http://bit.ly/cAHZ42
12/10/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

VFC's Stock House
Weekly Stock Watch- $AAPL, $AMRN, $DNDN, $IMSC.PK, $SGYP, $IRWD, $TTNP.OB, $LPTN, $PFE, $MCD, $YUM, $CELH.OB http://bit.ly/cAHZ42
12/9/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

VFC's Stock House
Stock Watch- $AMRN, $SGYP, $IRWD, $FRX, $SI, $TEV, $AZN, $IMSC.PK, $SIRI, $CTSO.OB, $GE, $JWM, $GMCR, $SBUX - http://bit.ly/Sqc8aL
11/28/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

VFC's Stock House
Weekly Stock Watch: $GE, $MCD, $IMSC.PK, $SSH, $F, $BBRY, $SGYP, $IRWD, $WMT, $BA, $GOOG - http://bit.ly/TYNiux
11/26/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Scott Matusow
My new article out @ http://seekingalpha.com/a/lb6d $BSDM $FOLD $SRPT $IRWD $THLD
11/9/12
Reply (12)

• !Report Abuse
View all 12 replies
drpharm: its legitimate, i have to wait until tomorrow, buts its okay, im on the upside overall because of your picks. its just a flesh wound haha
11/14/12
• !Report Abuse
StockMatusow: cool that is very MUCH a relief to hear!
11/14/12
• !Report Abuse
Add a reply...

140 characters

Red Acre Investments
$IRWD Linaclotide approved. $sgyp popped on the news - phase 3 results later this year = more upward movement to come
8/30/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Shane Blackmon
$SGYP trading nicely off of $IRWD approval. $SGYP should be trading near 10, not $5. Worth $25 on approval in 2-3 years.
8/30/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

nsahbti
IRWD internal Buys + opened 161 sales rep positions for hire. Guess they are highly optimistic. High target 22, low 7, mean 14.5. I'm in!
8/22/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Scott Matusow
My new article out @ http://seekingalpha.com/a/lb6d $BSDM $FOLD $SRPT $IRWD $THLD
11/9/12
Reply (12)

• !Report Abuse
View all 12 replies
drpharm: its legitimate, i have to wait until tomorrow, buts its okay, im on the upside overall because of your picks. its just a flesh wound haha
11/14/12
• !Report Abuse
StockMatusow: cool that is very MUCH a relief to hear!
11/14/12
• !Report Abuse
Add a reply...

140 characters

IRWD Ironwood Pharmaceuticals, Inc.

IRWD

Ironwood Pharmaceuticals, Inc.